This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here
HOME / ELIQUIS® (APIXABAN) DOSING INFORMATION ELIQUIS IRELAND / SWITCHING FROM AND TO ELIQUIS
Switching from and to ELIQUIS® (apixaban)
Choose ELIQUIS®
When switching to ELIQUIS please ensure you have considered the patient’s various factors that may influence the dosing of ELIQUIS e.g. indication, age, weight, renal function. See SmPC for full information.
Switching to ELIQUIS1
Switching to ELIQUIS
Please refer to the ELIQUIS Summary of Product Characteristics (SmPC) for more information.
ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.1
Footnotes:
BD = Twice Daily DOAC = Direct-acting Oral Anticoagulant INR = International Normalised Ratio SmPC = Summary of Product Characteristics UFH = Unfractionated Heparin
References:
- ELIQUIS® (apixaban) Summary of Product Characteristics.
- Steffel J et al. Eur Heart J 2018; 39: 1330–1393.
Date of Preparation: September 2025 | Job Description: 432-IE-2500027